(S)-(4,4-difluoro-3-(quinolin-2-yloxy)piperidin-1-yl)(1H-imidazo[4,5-c]pyridin-4-yl)methanone

ID: ALA3973097

Chembl Id: CHEMBL3973097

PubChem CID: 90298275

Max Phase: Preclinical

Molecular Formula: C21H17F2N5O2

Molecular Weight: 409.40

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(c1nccc2[nH]cnc12)N1CCC(F)(F)[C@@H](Oc2ccc3ccccc3n2)C1

Standard InChI:  InChI=1S/C21H17F2N5O2/c22-21(23)8-10-28(20(29)19-18-15(7-9-24-19)25-12-26-18)11-16(21)30-17-6-5-13-3-1-2-4-14(13)27-17/h1-7,9,12,16H,8,10-11H2,(H,25,26)/t16-/m0/s1

Standard InChI Key:  FEAVKDCRHLEQNS-INIZCTEOSA-N

Associated Targets(Human)

HCRTR2 Tclin Orexin receptor 2 (5902 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCRTR1 Tclin Orexin receptor 1 (5435 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Hcrtr1 Orexin receptor 1 (669 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hcrtr2 Orexin receptor 2 (79 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 409.40Molecular Weight (Monoisotopic): 409.1350AlogP: 3.43#Rotatable Bonds: 3
Polar Surface Area: 84.00Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.88CX Basic pKa: 3.34CX LogP: 2.98CX LogD: 2.98
Aromatic Rings: 4Heavy Atoms: 30QED Weighted: 0.56Np Likeness Score: -0.92

References

1. Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, McDonald TP, O'Brien J, Renger JJ, Williams PD, Winrow CJ, Coleman PJ..  (2016)  Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.,  26  (23): [PMID:27818110] [10.1016/j.bmcl.2016.10.019]
2. Préville C,Bonaventure P,Koudriakova T,Lord B,Nepomuceno D,Rizzolio M,Mani N,Coe KJ,Ndifor A,Dugovic C,Dvorak CA,Coate H,Pippel DJ,Fitzgerald A,Allison B,Lovenberg TW,Carruthers NI,Shireman BT.  (2020)  Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793.,  11  (10): [PMID:33062185] [10.1021/acsmedchemlett.0c00085]

Source